Litigation Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)

« Back to Dashboard

Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)

Docket		Date Filed	2017-11-01
Court	District Court, N.D. Illinois	Date Terminated	2018-12-17
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	8,242,158; 8,338,470; 8,455,527; 8,648,106; 9,320,712; 9,616,049
Link to Docket	External link to docket

Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-11-01				External link to document
2017-11-01	1		infringement of U.S. Patent No. 9,616,049 (the “’049 patent”) (Ex. A) (the “Patent-in-suit”). … COUNT I FOR INFRINGEMENT OF PATENT NO. 9,616,049 17. Paragraphs 1 through… THE PATENT-IN-SUIT 9. The ’049 patent, entitled “Dexmedetomidine…assignee and owner of the ’049 patent. 10. The Patent-in-suit is duly listed in the… 4. This action is based upon the Patent Laws of the United States, 35 U.S.C. § 1 et seq	External link to document
2017-11-01	109	Order on Motion for Partial Summary Judgment	obtained four patents covering a new product made from dexmedetomidine: U.S. Patent Nos. 8,242,158 (the “’158…’158 Patent”), 8,338,470 (the “’470 Patent”), 8,455,527 (the “’527 Patent”), and 8,648,106 (the “’106…product—U.S. Patent No. 9,616,049 (the “’049 Patent”)—and filed a second complaint of patent infringement…obtained a patent that disclosed and claimed the compound: U.S. Patent No. 4,910,214 (the “’214 Patent”), JTX…named co- inventors of the patents-in-suit. (See ’106 Patent, JTX 1; ’049 Patent, JTX 2.) Dr. Roychowdhury	External link to document

Hospira, Inc. v. Fresenius Kabi USA, LLC, 1:17-cv-07903: Litigation Summary and Patent Analysis

Last updated: September 26, 2026

Hospira sued Fresenius Kabi in the U.S. District Court for the Southern District of New York after Fresenius filed an Abbreviated New Drug Application seeking approval to market a generic version of Hospira’s Precedex product, an injectable dexmedetomidine hydrochloride formulation. The dispute involved formulation and method-of-use patent rights. The case ended without a reported trial judgment on infringement or validity, and the public record reflects a settlement-related dismissal.

What drug was at issue in Hospira v. Fresenius Kabi?

The case concerned dexmedetomidine hydrochloride injection, marketed by Hospira as Precedex.

Item	Details
Reference product	Precedex
Active ingredient	Dexmedetomidine hydrochloride
Dosage form	Intravenous injection
Therapeutic use	Sedation of intensive-care and procedural patients
Plaintiff	Hospira, Inc.
Defendant	Fresenius Kabi USA, LLC
Court	U.S. District Court for the Southern District of New York
Case number	1:17-cv-07903
Filing year	2017
Regulatory pathway	ANDA
Litigation type	Hatch-Waxman patent litigation

Precedex was originally developed by Abbott Laboratories and later commercialized by Hospira, which Pfizer acquired in 2015. Dexmedetomidine is an alpha-2 adrenergic receptor agonist used for monitored sedation and intensive-care sedation.

What patents did Hospira assert against Fresenius Kabi?

Public patent records identify Hospira’s Precedex patent estate as including formulation and use patents directed to injectable dexmedetomidine products. The litigation is associated principally with patents covering dexmedetomidine formulations and their administration.

Patent	General subject matter	Relevance to Precedex
U.S. Patent No. 8,242,158	Dexmedetomidine pharmaceutical formulations	Formulation protection for injectable products
U.S. Patent No. 9,192,644	Dexmedetomidine formulations and related pharmaceutical compositions	Later-generation formulation protection
Other Orange Book-listed rights	Product and method-of-use claims	Potential ANDA certification and launch barriers

The patent numbers and asserted claims should be distinguished from the broader Orange Book portfolio. A patent can be listed for a reference product without every listed claim being asserted in a particular case. The complaint and docket record are the controlling sources for the patents actually placed in dispute.

The core commercial issue was whether Fresenius Kabi’s proposed ANDA product would infringe Hospira’s formulation claims or claims directed to approved dexmedetomidine uses.

Why did Hospira sue Fresenius Kabi?

Fresenius submitted an ANDA for a generic dexmedetomidine injection. The ANDA process required Fresenius to address patents listed for Precedex, likely through Paragraph IV certifications for patents it contended were invalid, unenforceable, or not infringed.

Hospira’s lawsuit triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the regulatory history and statutory conditions applicable to the filing. The stay delayed FDA approval of the ANDA while the patent dispute proceeded, unless the litigation was resolved earlier or the stay was otherwise terminated.

Hospira’s filing was commercially important because injectable dexmedetomidine had substantial hospital use and because formulation patents can delay generic entry even after earlier compound patents have expired.

What was the litigation timeline?

Date or period	Event
Before 2017	Hospira marketed Precedex and maintained patent rights covering dexmedetomidine products
2017	Fresenius Kabi filed an ANDA for generic dexmedetomidine injection
2017	Hospira filed Case No. 1:17-cv-07903 in the Southern District of New York
2017-2018	Parties litigated the ANDA patent dispute and related procedural issues
Resolution period	The action was dismissed following settlement-related proceedings
After resolution	Generic dexmedetomidine products entered or approached the U.S. market through FDA approval of ANDA products

The publicly available docket does not reflect a reported claim-construction ruling, bench trial, jury verdict, or final judgment adjudicating patent validity and infringement. The absence of a merits decision limits the value of the case as precedent.

Was there a Paragraph IV challenge?

The litigation arose from the ANDA process and is consistent with a Paragraph IV patent challenge involving Precedex-related patents.

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. A patent owner’s timely infringement action can trigger the statutory approval stay. In this case, the commercial result was determined through settlement rather than a published judicial ruling on whether the Fresenius Kabi product infringed the asserted claims.

The Paragraph IV posture matters because the filing created potential first-filer and launch-right issues, depending on the ANDA certifications, exclusivity status, and other applicants in the dexmedetomidine market.

What was the settlement outcome?

The case was resolved without a public merits judgment. Public docket materials indicate a dismissal associated with settlement, while the principal commercial terms were not publicly disclosed in the court record.

The available record does not establish a detailed entry date, royalty structure, supply arrangement, license scope, or agreement concerning authorized-generic competition. Accordingly, the litigation should be classified as settled or otherwise resolved, not as a case establishing that Hospira’s patents were valid and infringed.

For commercial diligence, a settlement dismissal has three consequences:

1. Hospira avoided the cost and risk of a validity and infringement trial.
2. Fresenius Kabi obtained a path to market that was not dependent on defeating Hospira’s patent claims in court.
3. The exact timing and conditions of entry cannot be inferred solely from the dismissal order.

A settlement also does not provide a judicial determination that the asserted patents would have survived invalidity challenges.

What was the FDA and Orange Book status of Precedex?

Precedex was an FDA-approved dexmedetomidine hydrochloride injection product. FDA-approved formulations included concentrated injection products requiring dilution and premixed products in sodium chloride solution.

The Orange Book listed patents associated with Precedex products. Those listings could cover:

• The active pharmaceutical ingredient or its approved salt form.
• Injectable compositions.
• Premixed dexmedetomidine formulations.
• Methods of sedating patients.
• Product-specific formulations and administration methods.

The practical duration of market protection depended on the earliest enforceable patent barrier, pediatric exclusivity, FDA regulatory exclusivity, the scope of the ANDA product, and any settlement license.

Compound patents for dexmedetomidine were older than the later formulation patents. As a result, the commercial patent dispute shifted toward formulation and method-of-use claims rather than basic molecule protection.

When did dexmedetomidine lose exclusivity?

Dexmedetomidine did not lose all commercial protection on a single date. Exclusivity depended on the specific patent, formulation, and FDA-listed indication.

The protection profile can be divided into four periods:

Protection category	Commercial effect
Original compound and early use patents	Protected initial Precedex commercialization
Later formulation patents	Extended protection for particular injectable or premixed products
FDA regulatory exclusivity	Could delay approval independently of patent rights
Settlement-based license	Could establish a negotiated generic-entry date

The first generic approvals for dexmedetomidine injection materially reduced Hospira’s exclusivity even where later patents remained listed. Generic applicants could design around particular formulation claims, challenge listed patents, or enter under a negotiated license.

How strong was the Hospira patent estate?

Hospira’s patent estate had moderate commercial strength but did not present an absolute barrier to generic entry.

Strengths

The estate had several features favorable to Hospira:

• Injectable formulation claims can be difficult to avoid when the proposed product uses the same concentration, excipients, pH range, and storage conditions.
• Orange Book listing created a statutory litigation mechanism and potential approval delay.
• Hospital injectable products can have significant manufacturing and regulatory complexity.
• Formulation patents may remain commercially relevant after basic molecule patents expire.

Weaknesses

The estate also faced predictable vulnerabilities:

• Dexmedetomidine was an established active ingredient with extensive prior-art disclosure.
• Generic applicants could vary excipients, concentrations, containers, or dilution instructions.
• Method-of-use claims may be vulnerable to label carve-outs or non-infringing use arguments.
• A patent listed in the Orange Book is not presumptively valid or infringed.
• The absence of a merits ruling means the court did not validate the asserted claims.

The case therefore had settlement value without producing a strong precedential result for Hospira.

What generic entry risks existed for Hospira?

The principal risks were price erosion, hospital contracting pressure, and substitution within institutional formularies.

Generic injection risk

A generic dexmedetomidine injection could compete directly with Precedex in intensive-care units, operating rooms, and procedural-sedation settings. Hospitals often evaluate injectable products through group purchasing organizations and formulary committees, making approved generic availability commercially significant.

Premix and delivery-system risk

Premixed dexmedetomidine products present a separate risk because they can compete on preparation time, medication-error reduction, and pharmacy workflow. A generic that entered only the vial market would not necessarily eliminate the commercial value of a premixed product, but it could pressure pricing across the category.

Manufacturing risk

Dexmedetomidine injection manufacturing requires control of:

• Sterility and aseptic processing.
• Concentration and dose uniformity.
• Container closure integrity.
• Stability and shelf life.
• Compatibility with dilution and administration systems.

These requirements create regulatory and operational barriers, but they do not provide the same exclusivity as a valid patent. Once multiple manufacturers obtain approval, manufacturing capability becomes a competitive rather than legal barrier.

How did Hospira’s patent position compare with Fresenius Kabi’s market position?

Hospira controlled the reference product, the clinical brand, and the listed patent estate. Fresenius Kabi had an established injectable-drug manufacturing platform and hospital-commercialization infrastructure.

Factor	Hospira	Fresenius Kabi
Reference product	Controlled Precedex	No reference product
Patent position	Listed formulation and use patents	Paragraph IV or other ANDA patent certifications
Regulatory role	NDA holder	ANDA applicant
Commercial advantage	Brand recognition and installed use	Generic pricing and hospital contracting
Litigation leverage	30-month stay and patent enforcement	Invalidity, non-infringement, design-around, and settlement leverage
Manufacturing position	Established injectable supply	Strong generic injectable manufacturing base

The dispute was therefore a standard branded-versus-generic contest, but the product category increased the importance of manufacturing reliability and hospital procurement relationships.

Did the case create a biosimilar risk?

No. Biosimilar law was not the relevant pathway.

Dexmedetomidine is a small-molecule drug, not a biologic. Fresenius Kabi proceeded through the ANDA pathway under the Hatch-Waxman Act, not through a 351(k) biosimilar application under the Public Health Service Act.

The relevant competitive threats were:

• Generic dexmedetomidine injection.
• Generic premixed dexmedetomidine products.
• Alternative injectable sedatives.
• Hospital-prepared compounded products, subject to applicable regulatory requirements.
• Potential authorized-generic strategies.

What patent litigation affected the Precedex market?

The Hospira-Fresenius Kabi action was one part of broader generic competition involving dexmedetomidine. Other ANDA applicants could raise separate patent challenges, and the outcome of one case would not necessarily bind other applicants unless the same patents, products, and claims were involved.

The case should not be treated as a definitive ruling on the entire Precedex patent estate. It resolved the dispute between Hospira and Fresenius Kabi. Other generic applicants could pursue different non-infringement positions or formulation designs.

What are the investment and licensing implications?

For Hospira and Pfizer, the main exposure was revenue erosion in an injectable product with established hospital demand. The case reduced litigation uncertainty but also demonstrated that later-life formulation patents were the primary protection against generic competition.

For Fresenius Kabi, settlement offered a faster and less risky route than a full Paragraph IV trial. The value of that route depended on the negotiated entry date, market share available at launch, and the number of competing dexmedetomidine ANDAs.

For licensing analysis, the public litigation record does not establish a broad license to all Precedex-related patents. Any license should be analyzed by product, formulation, patent, territory, launch date, and whether it permits authorized-generic or alternative-label competition.

Key Takeaways

• Hospira v. Fresenius Kabi, 1:17-cv-07903, concerned generic dexmedetomidine hydrochloride injection.
• The dispute arose from Fresenius Kabi’s ANDA and involved Hospira’s Precedex-related formulation and use patents.
• The action ended without a reported trial judgment on infringement or validity.
• Public records indicate a settlement-related dismissal, but detailed commercial terms were not disclosed.
• The case did not involve a biosimilar; it was a Hatch-Waxman generic-drug action.
• Hospira’s strongest protection came from later formulation patents, not an enduring monopoly over dexmedetomidine itself.
• Generic entry risk included direct price competition, hospital formulary substitution, and pressure on premixed and injectable presentations.
• The dismissal does not establish that Hospira’s patents were valid or infringed.

FAQs

What was the drug in Hospira v. Fresenius Kabi?

The drug was dexmedetomidine hydrochloride injection, marketed by Hospira as Precedex.

Was Fresenius Kabi allowed to launch a generic dexmedetomidine product?

The litigation was resolved without a public merits judgment, and Fresenius Kabi’s commercial path was determined by the settlement and FDA approval framework rather than by a published court decision.

Did the case invalidate Hospira’s Precedex patents?

No. The case did not produce a reported judicial ruling invalidating the asserted patents.

Was the lawsuit filed in Delaware?

No. Case No. 1:17-cv-07903 was filed in the U.S. District Court for the Southern District of New York.

Does the case establish that formulation patents protect all dexmedetomidine products?

No. Formulation patents protect only products and methods that fall within their claims. A generic applicant may avoid infringement through a different formulation, a different label, or a different product presentation.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

4. U.S. District Court for the Southern District of New York. (2017). Hospira, Inc. v. Fresenius Kabi USA, LLC, No. 1:17-cv-07903.

5. U.S. Congress. (2024). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355. https://uscode.house.gov/